Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca 
Welcome,         Profile    Billing    Logout  
 32 Diseases   9 Trials   9 Trials   795 News 


12345678910111213»
  • ||||||||||  Review, Journal:  Atopic Dermatitis-Related Problems in Daily Life, Goals of Therapy and Deciding Factors for Systemic Therapy: A Review. (Pubmed Central) -  Nov 27, 2024   
    Recently, additional biologics have been evaluated in clinical trials, including lebrikizumab, nemolizumab, eblasakimab, and OX40/OX40L, among others...Available data also indicate the importance of a personalized, stepwise, and multidisciplinary approach. This type of approach promotes patient compliance, satisfaction with therapy, and increased engagement, which all lead to better patient outcomes.
  • ||||||||||  Review, Journal:  IL-13 inhibition in the treatment of atopic dermatitis - new and emerging biologic agents. (Pubmed Central) -  Nov 19, 2024   
    Eblasakimab, which disrupts IL-13 and IL-4 signaling pathways, is currently in phase II trials following well-tolerated administration in phase I studies. This narrative review aims to outline the current state of knowledge regarding the effectiveness and safety of these four biologic agents targeting IL-13 signaling.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Ebglyss (lebrikizumab-lbkz) / Eli Lilly
    Journal:  Not Available (Pubmed Central) -  Nov 18, 2024   
    This narrative review aims to outline the current state of knowledge regarding the effectiveness and safety of these four biologic agents targeting IL-13 signaling. No abstract available
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Journal:  An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024. (Pubmed Central) -  Nov 17, 2024   
    If a patient develops DROSD, there are clear pathways to assess severity and offer initial management; where ineffective, dermatologists should assess the urgency and seek advice from or initiate referral to ophthalmology. While the evidence reviewed for these guidelines reflects the extensive literature on dupilumab, we believe our advice has relevance for ocular surface disorders in atopic dermatitis (AD) patients treated with tralokinumab and lebrikizumab.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Journal, Real-world evidence, Real-world:  Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study. (Pubmed Central) -  Oct 3, 2024   
    Tralokinumab treatment showed prosperous therapeutic effects and good tolerability in real-world practice for AD, with higher effectiveness in patients without prior systemic therapy compared with those with prior systemic therapy. Tralokinumab treatment significantly decreased clinical and laboratory indexes, EASI, Peak Pruritus-Numerical Rating Scale, IgE, TARC, LDH, NLR, and SIRI.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
    Review, Journal:  Fungal Head and Neck Dermatitis: Current Understanding and Management. (Pubmed Central) -  Sep 24, 2024   
    OX40/OX40L inhibitors and tralokinumab may be promising options for HND on the horizon. Demographic and environmental factors influence the host mycobiome and should be considered in future precision-medicine approaches as microbiome composition and diversity are linked to severity of HND.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Blenrep (belantamab mafodotin-blmf) / GSK
    Journal, Adverse events, Real-world evidence, Real-world:  Drug-Related Keratitis: A Real-World FDA Adverse Event Reporting System Database Study. (Pubmed Central) -  Sep 20, 2024   
    Identifying the specific risks and timing of drug-induced keratitis can support the development of preventive measures. Identifying the specific drugs related to medication-related keratitis is of significant importance for drug vigilance in the occurrence of drug-related keratitis.
  • ||||||||||  Journal:  Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates. (Pubmed Central) -  Aug 22, 2024   
    They encourage a systematic approach for the diagnosis and treatment, using disease severity scores and quality-of-life measurement tools. Treatment recommendations take into consideration both established therapies and the approved systemic biologics dupilumab and tralokinumab, and the Janus kinase inhibitors baricitinib, upadacitinib, and abrocitinib.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Journal:  Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations. (Pubmed Central) -  Aug 20, 2024   
    Of interest, our cohort included oncologic patients, a patient with a history of severe infection, as well as subjects affected by severe neurological, psychiatric, pulmonary, and/or cardiovascular disease. Our experience showed that tralokinumab is effective and safe in elderly patients and subjects affected by severe comorbidities.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Journal:  Tralokinumab-induced injection-site reactions. (Pubmed Central) -  Aug 12, 2024   
    Tralokinumab treatment improved skin physiology, epidermal pathology and dysbiosis, further highlighting the pleiotropic role of IL-13 in AD pathogenesis. No abstract available
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Review, Journal:  Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab. (Pubmed Central) -  Aug 10, 2024   
    Tralokinumab leads to statistically significant improvements in disease severity and outcome scores. It represents an effective treatment option for adults with moderate to severe AD, but further large-scale studies are needed to verify long-term superiority over other treatments.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Successful treatment of hand and foot eczema with tralokinumab: a case series (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_2661;    
    Recently various case reports have shown the efficacy of dupilumab in the treatment of hand and foot eczema...All the patients have been advised to use topical steroids such as mometasone furoate and clobetasol propionate ointments in case of a flare of their hand and foot eczema... This case series of 5 patients highlights the off-label use of tralokinumab in hand and foot eczema.Tralokinumab had a rapid onset of action with decreased EASI scores and SCORAD within a month of initiating treatment leading to improvement in the patients
  • ||||||||||  German ADBest-TREAT Registry  (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_2402;    
    Of the 79% (n=86) receiving topical treatment, 42% (n=36) were treated with tacrolimus, 37% (n=32) with pimecrolimus, and 20% (n=17) with topical steroids... In this ADBest-TREAT registry cohort, the majority of AD patients received systemic therapy with a biologic, indicating that JAKi are not a dermatologist
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Charting a New Course: Tralokinumab in the Treatment of Refractory Hand Eczema (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_2392;    
    Tralokinumab may represent an effective treatment for this condition. Clinical trials are needed to assess the efficacy of biological therapies and available anti-JAKs for atopic dermatitis in hand eczema.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
    Psoriasiform reaction to dupilumab with good response and control of atopic dermatitis with tralokinumab (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_2326;    
    After treatment with multiple topicals and systemic drugs as methotrexate, azathioprine and cyclosporine without control of the disease, it was decided to start dupilumab (EASI 25, BSA 62%, IGA 4, pruritus 8)...Treatment with cyclosporine, upadacitinib, baricitinib and abrocitinib were tried without achieving control of the atopic dermatitis and developing, on the other side, severe outbreaks of herpes simplex... Treatment with tralokinumab is presented as an alternative option to JAK inhibitors for patients who have experienced psoriasiform reactions attributed to dual inhibition of IL-4-/IL-13, as suppression of IL-4 can partly explain the occurrence of these reactions due to the disinhibition of IL-23/IL-17 axis.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Two-Year Multicenter Study on Tralokinumab: Drug Survival, Safety and Efficacy in Severe Atopic Dermatitis (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_2295;    
    Overall, the study suggests that tralokinumab treatment led to significant improvements in both clinical manifestations and patient-reported outcomes in patients with atopic dermatitis. However, there were variations in response rates and tolerability among patients, especially those with prior treatment experience.